Drugs / Cvac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01068509 | Jul 2010 → Aug 2013 | malignant epithelial tumor of ovary | Prima BioMed Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVac | “BACKGROUND: CAN-003 was a randomized, open-label, Phase 2 trial evaluating the safety, efficacy and immune outcomes of CVac, a mucin 1 targeted-dendritic cell (DC) treatment as...” PMID 27330807 ↗ Jun 2016 |
| Modality | Cell therapy | “mucin 1 targeted-dendritic cell (DC) treatment” PMID 27330807 ↗ Jun 2016 |
| Route | Other | “Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs.” NCT01068509 ↗ |
| Target | MUC1 | “to target the DCs to the specific mucin 1 antigen” NCT01068509 ↗ |